MarketWatch report “B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, announced that it received U.S. Food and Drug Administration (FDA) approval for 500mg Meropenem for Injection USP and Sodium Chloride Injection USP and 1g Meropenem for Injection USP and Sodium Chloride Injection USP in B. Braun’s DUPLEX(R) Container.
BBraun receives FDA approval to offer Meropenem in its DUPLEX(R) container http://ctt.ec/Z45O7+ @ivteam #ivteam
“This approval allows us to offer healthcare providers a convenient, ready-to-use option to deliver Meropenem to patients via our DUPLEX container,” said Rick Williamson, Vice President of Pharmaceutical Marketing at B.Braun. “This will eliminate the need to compound or batch Meropenem vials, resulting in reduced waste, compounding time and reducing medication errors,” added Williamson.”Full Story
Thank you to our partners for supporting IVTEAM